A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Solid Tumor
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +3.8
A key executive is leaving
Since Jul 9, 2026 · was worth 15, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 500 (planned)
- Started
- Apr 22, 2024
- Main results expected
- Feb 2028
- Fully finished
- Feb 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Number of patients with adverse events (AEs)
Measured over: Through study completion, estimated as an average of 47 months
Phase 1: Recommended doses or schedules for expansion (RDEs) and maximum tolerated dose (MTD)
Measured over: Approximately 15 months
Phase 2: Objective Response Rate (ORR) for BHV-1510 for monotherapy and in combination with cemiplimab
Measured over: Through study completion, estimated as an average of 47 months
Phase 2: Number of patients with AEs for BHV-1510 for monotherapy and in combination with cemiplimab
Measured over: Through study completion, estimated as an average of 47 months
Phase 2: Duration of Response (DoR) for BHV-1510 for monotherapy and in combination with cemiplimab
Measured over: Through study completion, estimated as an average of 47 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 3.8, since 2026-07-09, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT06384807 · record last updated 2026-09-28 · checked 2026-11-09 15:47 UTC